Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept with Chemoradiation and FOLFOX6 in Rectal Cancer
NCT01749956Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2013
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in rectal cancer, sponsored by SCRI Development Innovations. Started Jan 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01749956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01749956.